These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12934778)

  • 1. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
    Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
    Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
    Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
    J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
    Reiz JL; Salem P; Darke AC
    J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.
    Sathyan G; Chancellor MB; Gupta SK
    Br J Clin Pharmacol; 2001 Oct; 52(4):409-17. PubMed ID: 11678784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
    Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S
    J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
    Oki T; Toma-Okura A; Yamada S
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
    Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
    Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal oxybutynin: a new treatment for overactive bladder.
    Davila GW
    Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
    Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
    J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate.
    Chancellor MB; Appell RA; Sathyan G; Gupta SK
    Clin Ther; 2001 May; 23(5):753-60. PubMed ID: 11394733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.
    Zobrist RH; Schmid B; Feick A; Quan D; Sanders SW
    Pharm Res; 2001 Jul; 18(7):1029-34. PubMed ID: 11496941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of percutaneous and intraduodenal administration of oxybutynin on bladder contraction and salivation in rabbits.
    Kontani H; Hamamoto T; Takeuchi S; Nomura Y; Sawanishi H; Saito H
    Int J Urol; 2006 Jul; 13(7):977-84. PubMed ID: 16882066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in medical management of overactive bladder.
    Richelson E; Elliott DS
    Mayo Clin Proc; 2003 Jun; 78(6):681-3. PubMed ID: 12934775
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder.
    Preik M; Albrecht D; O'Connell M; Hampel C; Anderson R
    BJU Int; 2004 Oct; 94(6):821-7. PubMed ID: 15476516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.